Legal & General Group Plc Raises Stock Position in Bristol Myers Squibb Company $BMY

Legal & General Group Plc grew its stake in Bristol Myers Squibb Company (NYSE:BMY) by 8.4% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 17,075,743 shares of the biopharmaceutical company’s stock after purchasing an additional 1,317,199 shares during the quarter. Legal & General Group Plc owned about 0.84% of Bristol Myers Squibb worth $770,116,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Norges Bank purchased a new position in shares of Bristol Myers Squibb during the second quarter valued at about $1,554,154,000. Charles Schwab Investment Management Inc. lifted its holdings in Bristol Myers Squibb by 16.8% in the second quarter. Charles Schwab Investment Management Inc. now owns 70,802,680 shares of the biopharmaceutical company’s stock worth $3,277,456,000 after buying an additional 10,195,775 shares during the period. Arrowstreet Capital Limited Partnership boosted its position in Bristol Myers Squibb by 428.5% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 11,311,281 shares of the biopharmaceutical company’s stock valued at $523,599,000 after acquiring an additional 9,171,098 shares in the last quarter. Man Group plc boosted its position in Bristol Myers Squibb by 280.4% during the 2nd quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company’s stock valued at $345,594,000 after acquiring an additional 5,503,391 shares in the last quarter. Finally, Franklin Resources Inc. raised its position in shares of Bristol Myers Squibb by 142.8% in the 2nd quarter. Franklin Resources Inc. now owns 8,436,811 shares of the biopharmaceutical company’s stock worth $390,541,000 after acquiring an additional 4,961,869 shares in the last quarter. Institutional investors own 76.41% of the company’s stock.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: FDA approves an expanded label for Sotyktu (BMY’s TYK2 inhibitor) for psoriatic arthritis after strong POETYK data — this broadens the drug’s commercial opportunity and supports revenue growth for the immunology portfolio. BMY Wins FDA Nod to Expand Sotyktu Label for Psoriatic Arthritis
• Positive Sentiment: Positive Phase 3 SUCCESSOR-2 results for oral mezigdomide in relapsed/refractory multiple myeloma — a successful registrational trial materially improves approval and commercialization prospects for this CELMoD asset. Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study
• Positive Sentiment: Late‑stage cancer trial met its primary endpoint and another trial reported improved survival in a late‑stage blood cancer study — these clinical successes reduce execution risk and increase the potential for new oncology approvals and revenue. Bristol’s cancer treatment meets main goal in late-stage trial Bristol’s drug enhances survival rates in late-stage blood cancer trial
• Neutral Sentiment: Market commentary and investor interest pieces (Zacks/Yahoo) note heightened attention in BMY and review valuation/earnings outlooks — these can drive trading volume but are not new company catalysts by themselves. Is Trending Stock Bristol Myers Squibb Company (BMY) a Buy Now? Is Trending Stock Bristol Myers Squibb Company (BMY) a Buy Now?
• Neutral Sentiment: Analysts maintain a consensus “Hold” on BMY — indicates mixed views on valuation vs. growth prospects despite recent clinical wins. Bristol Myers Squibb Company Given Consensus Rating of “Hold”
• Neutral Sentiment: Longer-form investor coverage (Fool) credits BMY’s growth portfolio for offsetting legacy declines and highlights development progress — useful context for medium-term thesis but not an immediate catalyst. Why Bristol Myers Squibb Stock Crushed it in February
• Neutral Sentiment: Broader industry report on anticoagulants shows market growth but is not specific to BMY’s pipeline/products and is therefore a background industry tailwind rather than a direct company catalyst. Anticoagulants Market Competitive Analysis Report 2025
• Neutral Sentiment: Third‑party portfolio review (Virtus Large Cap Growth SMA) mentions overall fund performance; BMY was not a highlighted driver and the item is unlikely to move BMY stock materially. Virtus Large Cap Growth SMA Q4 2025 Portfolio Review

Wall Street Analyst Weigh In

A number of research firms have recently commented on BMY. Scotiabank restated a “sector perform” rating and issued a $60.00 target price (up from $53.00) on shares of Bristol Myers Squibb in a research note on Friday, January 9th. Morgan Stanley reiterated an “underweight” rating and issued a $40.00 price objective on shares of Bristol Myers Squibb in a report on Friday, February 6th. Wells Fargo & Company reissued an “outperform” rating and set a $60.00 price objective (up from $55.00) on shares of Bristol Myers Squibb in a research report on Friday, February 6th. UBS Group reaffirmed a “buy” rating and issued a $70.00 target price on shares of Bristol Myers Squibb in a research report on Friday. Finally, Citigroup increased their price target on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “neutral” rating in a research note on Friday, February 6th. Nine equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $61.00.

Bristol Myers Squibb Trading Up 0.5%

NYSE:BMY opened at $60.59 on Tuesday. The stock has a market cap of $123.38 billion, a price-to-earnings ratio of 17.56, a PEG ratio of 0.17 and a beta of 0.26. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32. The company’s 50 day moving average price is $57.79 and its 200-day moving average price is $51.12. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). The firm had revenue of $12.50 billion during the quarter, compared to analysts’ expectations of $12.24 billion. Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.Bristol Myers Squibb’s revenue was up 1.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.67 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities research analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be paid a $0.63 dividend. The ex-dividend date is Thursday, April 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.2%. Bristol Myers Squibb’s payout ratio is currently 73.04%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.